To review the current management of women with breast pain.
The effect of various treatment modes and health practices, including medications, was considered for the management of both cyclical and noncyclical breast pain.
Effective and timely management of the woman with breast pain and improved quality of life.
A literature search was performed to identify reports published in English between 1975 and July 2003 using MEDLINE and Cochrane Database of Systematic Reviews.
Levels of evidence, as outlined, have been determined using the criteria outlined by the Canadian Task Force on the Periodic Health Examination. Participants were the principal authors: a clinical dietitian, a surgeon oncologist, and a nurse.
Utilizing the information will increase knowledge, enabling a consistent approach, which will reduce the number of ineffective interventions and ensure appropriate use medications.
Comparison has been made with management protocols in the literature, but no clinical guidelines have been located. No formal clinical testing has taken place.
The Society of Obstetricians and Gynaecologists of Canada (SOGC). Work on these guidelines was initiated by team members to fill a need for practice guidelines at Winnipeg Regional Health Authority Breast Health Centre, Winnipeg, MB.
1. Education and reassurance is an integral part of the management of mastalgia and should be the first-line treatment. (II-1 A) 2. The use of a well-fitting bra that provides good support should be considered for the relief of cyclical and noncyclical mastalgia. (II-3 B) 3. A change in dose, formulation, or scheduling should be considered for women on HRT. HRT may be discontinued if appropriate. (III C) 4. Women with breast pain should not be advised to reduce caffeine intake. (1 E) 5. Vitamin E should not be considered for the treatment of mastalgia. (1 E) 6. There is presently insufficient evidence to recommend the use of evening primrose oil (EPO) in the treatment of breast pain. (II-2 C) 7. Flaxseed should be considered as a first-line treatment for cyclical mastalgia. (I A) 8. Topical non-steroidal anti-inflammatory gel, such as diclofenac 2% in pluronic lethicin organogel, should be considered for pain control for localized treatment of mastalgia. (I A) 9. Tamoxifen 10 mg daily or danazol 200 mg daily should be considered when first-line treatments are ineffective. (I A) 10. Mastectomy or partial mastectomy should not be considered an effective treatment for mastalgia. (III E).
AuthorsVera Rosolowich, Elizabeth Saettler, Beth Szuck, Robert H Lea, Pierre Levesque, Fay Weisberg, James Graham, Lynne McLeod, Vera Rosolowich,
JournalJournal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC (J Obstet Gynaecol Can) Vol. 28 Issue 1 Pg. 49-71; quiz 58-60, 72-4 (Jan 2006) ISSN: 1701-2163 [Print] Canada
PMID16533457 (Publication Type: Journal Article, Practice Guideline)
Chemical References
  • Toremifene
  • Breast Diseases (complications)
  • Breast Neoplasms (complications)
  • Canada
  • Evidence-Based Medicine
  • Female
  • Gynecology (standards)
  • Humans
  • Menstruation Disturbances (complications)
  • Pain (etiology, psychology)
  • Pain Management
  • Pain Measurement
  • Quality of Life
  • Societies, Medical
  • Toremifene (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: